HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO • US40637H1095

70.36 USD
-0.28 (-0.4%)
At close: Feb 24, 2026
70.36 USD
0 (0%)
After Hours: 2/24/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

HALO gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make HALO suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year HALO was profitable.
  • HALO had a positive operating cash flow in the past year.
  • HALO had positive earnings in each of the past 5 years.
  • In the past 5 years HALO always reported a positive cash flow from operatings.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

1.2 Ratios

  • The Return On Assets of HALO (12.55%) is better than 94.24% of its industry peers.
  • The Return On Equity of HALO (649.18%) is better than 99.81% of its industry peers.
  • HALO has a better Return On Invested Capital (25.65%) than 98.46% of its industry peers.
  • HALO had an Average Return On Invested Capital over the past 3 years of 20.76%. This is above the industry average of 18.24%.
  • The last Return On Invested Capital (25.65%) for HALO is above the 3 year average (20.76%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROIC 25.65%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • With an excellent Profit Margin value of 22.69%, HALO belongs to the best of the industry, outperforming 94.63% of the companies in the same industry.
  • In the last couple of years the Profit Margin of HALO has declined.
  • With an excellent Operating Margin value of 58.45%, HALO belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Operating Margin of HALO has grown nicely.
  • Looking at the Gross Margin, with a value of 83.62%, HALO belongs to the top of the industry, outperforming 86.95% of the companies in the same industry.
  • HALO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
  • Compared to 1 year ago, HALO has less shares outstanding
  • Compared to 5 years ago, HALO has less shares outstanding
  • The debt/assets ratio for HALO is higher compared to a year ago.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • HALO has an Altman-Z score of 3.96. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.96, HALO is in the better half of the industry, outperforming 70.25% of the companies in the same industry.
  • HALO has a debt to FCF ratio of 6.00. This is a slightly negative value and a sign of low solvency as HALO would need 6.00 years to pay back of all of its debts.
  • HALO has a Debt to FCF ratio of 6.00. This is amongst the best in the industry. HALO outperforms 91.55% of its industry peers.
  • HALO has a Debt/Equity ratio of 43.89. This is a high value indicating a heavy dependency on external financing.
  • HALO has a Debt to Equity ratio of 43.89. This is amonst the worse of the industry: HALO underperforms 81.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Altman-Z 3.96
ROIC/WACC3.41
WACC7.52%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

  • HALO has a Current Ratio of 4.66. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • HALO's Current ratio of 4.66 is in line compared to the rest of the industry. HALO outperforms 53.74% of its industry peers.
  • HALO has a Quick Ratio of 3.66. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of HALO (3.66) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 3.66
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • HALO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.36%.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 35.63% on average per year.
  • HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.55%.
  • Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 39.16% on average per year.
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%

3.2 Future

  • HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.28% yearly.
  • The Revenue is expected to grow by 5.67% on average over the next years.
EPS Next Y101.78%
EPS Next 2Y54.48%
EPS Next 3Y35.8%
EPS Next 5Y17.28%
Revenue Next Year26.89%
Revenue Next 2Y19.59%
Revenue Next 3Y12.37%
Revenue Next 5Y5.67%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 17.04, HALO is valued on the expensive side.
  • Based on the Price/Earnings ratio, HALO is valued cheaply inside the industry as 95.59% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 26.98, HALO is valued a bit cheaper.
  • HALO is valuated reasonably with a Price/Forward Earnings ratio of 8.44.
  • HALO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 98.27% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.01. HALO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 17.04
Fwd PE 8.44
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 95.01% of the companies in the same industry.
Industry RankSector Rank
P/FCF 23.19
EV/EBITDA 11.35
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of HALO may justify a higher PE ratio.
  • A more expensive valuation may be justified as HALO's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)0.17
PEG (5Y)0.48
EPS Next 2Y54.48%
EPS Next 3Y35.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HALO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (2/24/2026, 8:00:01 PM)

After market: 70.36 0 (0%)

70.36

-0.28 (-0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners105.85%
Inst Owner Change-19.66%
Ins Owners0.81%
Ins Owner Change0.27%
Market Cap8.27B
Revenue(TTM)1.40B
Net Income(TTM)316.89M
Analysts76
Price Target86.19 (22.5%)
Short Float %11.63%
Short Ratio6.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-53.57%
Min EPS beat(2)-110.7%
Max EPS beat(2)3.56%
EPS beat(4)3
Avg EPS beat(4)-18.27%
Min EPS beat(4)-110.7%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)-1.32%
EPS beat(12)9
Avg EPS beat(12)0.23%
EPS beat(16)12
Avg EPS beat(16)2.67%
Revenue beat(2)2
Avg Revenue beat(2)1.65%
Min Revenue beat(2)1.13%
Max Revenue beat(2)2.18%
Revenue beat(4)4
Avg Revenue beat(4)6.95%
Min Revenue beat(4)1.13%
Max Revenue beat(4)12.81%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)8
Avg Revenue beat(12)3.65%
Revenue beat(16)10
Avg Revenue beat(16)2.56%
PT rev (1m)1.13%
PT rev (3m)4.62%
EPS NQ rev (1m)15.2%
EPS NQ rev (3m)14.6%
EPS NY rev (1m)4.8%
EPS NY rev (3m)6.45%
Revenue NQ rev (1m)11.18%
Revenue NQ rev (3m)11.04%
Revenue NY rev (1m)3.44%
Revenue NY rev (3m)5.06%
Valuation
Industry RankSector Rank
PE 17.04
Fwd PE 8.44
P/S 5.92
P/FCF 23.19
P/OCF 12.7
P/B 169.51
P/tB N/A
EV/EBITDA 11.35
EPS(TTM)4.13
EY5.87%
EPS(NY)8.33
Fwd EY11.84%
FCF(TTM)3.03
FCFY4.31%
OCF(TTM)5.54
OCFY7.87%
SpS11.88
BVpS0.42
TBVpS-12.87
PEG (NY)0.17
PEG (5Y)0.48
Graham Number6.21
Profitability
Industry RankSector Rank
ROA 12.55%
ROE 649.18%
ROCE 34.76%
ROIC 25.65%
ROICexc 27.31%
ROICexgc 93.59%
OM 58.45%
PM (TTM) 22.69%
GM 83.62%
FCFM 25.55%
ROA(3y)16.77%
ROA(5y)19.55%
ROE(3y)369.08%
ROE(5y)286.14%
ROIC(3y)20.76%
ROIC(5y)19.08%
ROICexc(3y)25.83%
ROICexc(5y)35.19%
ROICexgc(3y)78.99%
ROICexgc(5y)74.81%
ROCE(3y)28.13%
ROCE(5y)25.85%
ROICexgc growth 3Y19.79%
ROICexgc growth 5YN/A
ROICexc growth 3Y19.91%
ROICexc growth 5YN/A
OM growth 3Y10.06%
OM growth 5Y1.62%
PM growth 3Y-9.5%
PM growth 5Y-14%
GM growth 3Y1.96%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 43.89
Debt/FCF 6
Debt/EBITDA 2.37
Cap/Depr 334.74%
Cap/Sales 21.1%
Interest Coverage 71.42
Cash Conversion 72.05%
Profit Quality 112.6%
Current Ratio 4.66
Quick Ratio 3.66
Altman-Z 3.96
F-Score5
WACC7.52%
ROIC/WACC3.41
Cap/Depr(3y)121.97%
Cap/Depr(5y)85.12%
Cap/Sales(3y)8%
Cap/Sales(5y)5.01%
Profit Quality(3y)116.88%
Profit Quality(5y)108.21%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
EPS Next Y101.78%
EPS Next 2Y54.48%
EPS Next 3Y35.8%
EPS Next 5Y17.28%
Revenue 1Y (TTM)37.55%
Revenue growth 3Y28.38%
Revenue growth 5Y39.16%
Sales Q2Q%51.6%
Revenue Next Year26.89%
Revenue Next 2Y19.59%
Revenue Next 3Y12.37%
Revenue Next 5Y5.67%
EBIT growth 1Y48.02%
EBIT growth 3Y41.29%
EBIT growth 5Y41.42%
EBIT Next Year40.15%
EBIT Next 3Y22.4%
EBIT Next 5Y3.88%
FCF growth 1Y-23.82%
FCF growth 3Y14.89%
FCF growth 5Y46.43%
OCF growth 1Y36.01%
OCF growth 3Y39.48%
OCF growth 5Y63.66%

HALOZYME THERAPEUTICS INC / HALO FAQ

Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 7 / 10 to HALO.


Can you provide the valuation status for HALOZYME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.


Can you provide the profitability details for HALOZYME THERAPEUTICS INC?

HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 9 / 10.


What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?

The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 7 / 10.


Can you provide the expected EPS growth for HALO stock?

The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 101.78% in the next year.